Despite a number of attempts to improve treatment of ovarian cancer, it remains the most common cause of death from gynecological cancers. Thus, it is very important to identify more effective drugs for treatment and prevention of ovarian cancer. All-trans-retinoic acid (ATRA) has been shown to arrest the growth of ovarian carcinoma cells in G0/G1 and to significantly elevate levels of Rb2/p130 protein, a member of the retinoblastoma family of tumor suppressors. As ATRA treatment leads to a significant increase in the amount of Rb2/p130 protein but not mRNA, the elevated levels of Rb2/p130 protein is likely the result of increased stability. In studies to elucidate the mechanism by which ATRA alters Rb2/ p130 stability in ovarian cancer cells, it was determined that PP2A, a serine/threonine phosphatase, binds and dephosphorylates Rb2/p130. Dephosphorylated Rb2/p130 exhibits decreased ubiquitination and thus is not degraded by the proteasome. The sites at which PP2A catalytic subunit (PP2Ac) interacts with Rb2/p130 have been localized to the NLS in the C-terminus of Rb2/p130. These sites are also involved in the interaction of Rb/p130 with importin b and importin a, members of the nuclear transport machinery. It is known that importin a recognizes a NLS on a target protein and importin b binds the nuclear pore complex. Moreover, it has been shown that the binding of importin a to NLS significantly decreases with phosphorylation of NLS. In ATRA-treated ovarian carcinoma cells, PP2A binds to Rb2/p130 and dephosphorylates the NLS of Rb2/p130 leading to the interaction of importin a with Rb2/p130. Importin b then binds to the importin a-Rb2/p130 complex, leading to the translocation of the Rb2/p130 to the nucleus where it acts to arrest ovarian cancer cells in G1 and suppress proliferation.
The Rb2/p130 phosphoprotein is a member of the retinoblastoma (Rb) family of tumor suppressors. The three members of this family share a high degree of homology both in composition and in method of action (Paggi et al., 1996; Sidle et al., 1996; Mayol and Grana, 1997; Nevins, 1998) . These 'pocket' proteins maintain order at the G1 checkpoint of the cell cycle primarily through their ability to bind and sequester members of the E2F family of transcription factors (Moberg et al., 1996; Sidle et al., 1996; Corbeil and Branton, 1997; Mayol and Grana, 1998; Stiegler and Giordano, 1999) which control the expression of genes involved in cell cycle progression (see also Giacinti and Giordano, in this issue).
The highly conserved pocket structure of Rb2/p130 is made up of the A and B domains, separated by a spacer region. This sequence is well known for its ability to bind LXCXE containing motifs (Dahiya et al., 2000) . It is the A and B domain that define the minimal sequence necessary for binding to the LXCXE motif. A variety of normal cellular proteins, which interact with the Rb family contain this sequence. These include histone deacetylase 1 (Rayman et al., 2002) , protein phosphatase 1 (Dunaief et al., 2002) , and BRCA1 (Fan et al., 2001) . Many viral proteins such as adenovirus E1A (Nielsch et al., 1991; Guilhot et al., 1993; Missero et al., 1993; Putzer et al., 1997; Rumpf et al., 1999) , human papiloma virus E7 (Banks et al., 1990; Schmitt et al., 1994; Jones et al., 1997; Wang et al., 1997; Liu et al., 2000) , and SV40 large T antigen (Hu et al., 1990) contain this sequence and as such are also able to bind to the Rb family of proteins.
One important mechanism controlling the G0/G1 checkpoint is the phosphorylation of the Rb family by G1 cyclin/CDK complexes. The three members of the Rb protein family all contain multiple serine or threoine residues that can be recognized and phosphorylated by cyclin-dependent kinases (CDJs) (Sidle et al., 1996) . Hypophosphorylated Rb proteins bind to and sequester E2F in the G0/G1 phase of the cell cycle. Increased phosphorylation of Rb proteins decreases the affinity to E2F, which is released, allowing the cell cycle to progress. Hyperphosphorylation of Rb2/p130 results in degradation of the protein through the ubiquitin proteasomal pathway (Ludlow et al., 1993; Grana, 1997, 1998; Smith et al., 1998; Vuocolo et al., 2003; ) . In addition, phosphorylation by CDK disrupts the binding of HDAC1 to Rb proteins, which leads to a relaxed chromatin state and makes it accessible to transcription factors and cells proliferate (Ferreira et al., 1998) . In vivo phosphorylation mapping of human Rb2/ p130 has identified 22 serine and threonine residues which are targets for cyclin A/Cdk2 and cyclin D/Cdk 4 (Hansen et al., 2001) (Figure 1 ). In addition, it has been observed that Rb2/p130 is also specifically phosphorylated in G0-arrested cells (Litovchick et al., 2004) by glycogen synthase kinase 3 (GSK3). Phosphorylation of Rb2/p130 by GSK3 contributes to the stability of the protein, but did not affect the interaction with E2F4 or cyclins (Litovchick et al., 2004) . It is clear that regulation of Rb proteins by phosphorylation is significantly complex and requires more intensive investigation.
Protein phosphatase 2A
It is well established that phosphorylation of proteins is a major regulatory mechanism in the cell and is a dynamic process controlled by kinases and phosphatases. Protein phosphatase (PP) 2A is a major serine/ threonine phosphatase, which dephosphorylates serine and threonine residues in a protein. Its activity is highly regulated and is involved in numerous cellular activities such as cell cycle regulation, apoptosis, signal transduction, stress response, heat shock response and DNA damage response (Mumby and Walter, 1993; Mumby, 1995; Wera and Hemmings, 1995; Janssens and Goris, 2001 ). The PP2A holoenzyme is a trimeric protein and consists of three subunits: A, B and C (Figure 2 ). The C or catalytic subunit (PP2Ac) is a 36 kDa protein which exhibits actual serine/threonine phosphatase activity and remained remarkably conserved throughout evolution. There are two isoforms of PP2Ac which are designated a and b. While these share 97% homology, the a isoform is 10 times more abundant than the b isoform (Janssens and Goris, 2001) .
Scaffolding or A subunit also has two isoforms designated a and b, which share 86% homology and are ubiquitously expressed. The A subunit, a protein of 65 kDa allows PP2Ac to interact with various B or regulatory subunits. B subunits define substrate specificity, cell localization and stability of PP2A enzyme (Voorhoeve et al., 1999; Janssens and Goris, 2001; Strack et al., 2002) . A growing number of variable regulatory subunits of PP2A exist. Different isoforms of regulatory B subunits as well as A and C subunits give a number of possible combinations of the PP2A enzyme. PP2A is the most abundant phosphatase in cells. It is highly regulated at the transcriptional level as well as by post-translational modifications.
Retinoids
Retinoids are a group of natural and synthetic derivatives of vitamin A. There are hundreds of different compounds that belong to this group. Vitamin A and its retinoid derivatives play an essential role in many of the body's important processes. Vision, immune function, T417   S413   T401   S662   T642   S639   S672   S688   T694   S1068   S1044   S1035   S1080   T1097   S1112   S962   S952   S948   S966   S973   S982   T986 
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Figure 1 Schematic summary of the location of the 22 serine and threonine resides mapped by in vivo phosphorylation assays of Rb2/p130. In vivo phosphorylation mapping of human Rb2/p130 has identified 22 serine and threonine residues which are targets for cyclinA/Cdc2 and cyclinD/Cdk4 (Adapted from Hansen et al., 2001 Retinoids can be divided into three structural moieties: a polar terminus, a conjugated side chain, and a b-ionone (cyclohexenyl) ring (Figure 3a) . These structural moieties cause retinoids to be hydrophobic and unstable in the presence of oxygen and low pH. Retinoids are also unstable in light, and are sensitive to isomerization via the activity of various enzymes. Retinol, retinal, and all-trans-retinoic acid (ATRA) are among the most important natural retinoids. Retinol, the alcohol form of vitamin A, is the major transport form Retinal, the aldehyde form active in vision, is produced by an enzymatic oxidation of retinol in a variety of tissues, or by a direct cleavage of dietary bcarotene in the small intestine and liver. If the need exists, retinal can be converted back to retinol through a reduction reaction by retinaldehyde reductase. In contrast, further oxidation of retinal into ATRA by retinal dehydrogenase is an irreversible step. Other natural retinoids include 9-cis and 13-cis retinoic acid (Figure 3b ). These compounds are isomers of ATRA and have differing functions. This helps explain the multiple of activities, which are attributed to retinoids. It is also interesting to note that except for the activities of retinoids in vision and reproduction, all of the actions of vitamin A can be accomplished by ATRA alone.
Synthetic retinoids have some or all of the biological properties of natural retinoids as well as other important biological activities. One of these activities is the induction of apoptosis (Sheikh et al., 1995; Fanjul et al., 1996; Wu et al., 1998a; Holmes et al., 2000 Holmes et al., , 2002 Holmes et al., , 2003a Holmes et al., 2004) . Synthetic retinoids are defined as man-made compounds that are structurally and functionally similar to natural retinoids (Dawson and Hobbs, 1994) . Thousands of bioactive retinoid derivatives have been synthesized over the past two decades that have potential in the treatment of abnormal tissues (Dawson and Hobbs, 1994) . Thousands of bioactive retinoid derivatives have been synthesized over the past two decades that have potential in the treatment of abnormal tissues (Dawson and Hobbs, 1994) . Synthetic retinoids can act as agonists or antagonists in either a pan-or selective retinoid receptor binding. In order for a retinoid to be selective, it must be used in appropriate concentration because at high concentrations, binding will occur with retinoid receptors in a non-selective manner. It has never been shown that synthetic retinoids require transport proteins for delivery to tissues during treatments, and it is widely believed that all retinoids enter cells through passive diffusion. Owing to the hydrophobic nature of retinoids, they tend to associate with lipophilic cellular structures. These attributes in general may account for the need for higher concentrations of retinoids for intravenous treatments of carcinomas and the ability to use retinoids for topical epithelial cell treatments.
Ovarian cancer
Ovarian cancer is the most common cause of death from gynecological cancers in the US, representing 55% of all gynecologic cancer deaths (Jemal et al., 2005) . 22 220 new cases of ovarian cancer and 16 210 estimated deaths of ovarian cancer reported in 2005 (Jemal et al., 2005) . The 5-year survival rate of ovarian cancer is only about 40%. This is a result of the fact that ovarian cancer is generally detected at an advanced stage (Ford et al., 1995; Modugno, 2003) . A consequence of the relatively late-stage diagnosis of ovarian cancer is that over 70% of ovarian cancers exhibit some evidence of distant regional involvement at the time of diagnosis (Daly and Obrams, 1998) . Poor long-term prognosis is also a reflection of the lack of effective prevention and therapy (Tortolero-Luna and Mitchell, 1995; Modugno, 2003) .
As ovarian cancer is often asymptomatic in its early stages, most patients have widespread disease at the time of diagnosis. The sooner ovarian cancer is diagnosed and treated, the better a woman's chance for recovery. Many times, women with ovarian cancer have no symptoms or just mild symptoms until the disease reaches an advanced stage. Detection of CA-125 tumor marker, biopsy, lower GI series, transvaginal ultrasound and combination of these methods may help to detect disease earlier.
Current treatments used for ovarian cancer are highly toxic and not very efficient. Surgery and following chemotherapy and radiotherapy are the usual initial treatment for women diagnosed with ovarian cancer. (McGuire, 1998; Young and Plosker, 2001 ). The surgery is an invasive procedure and has many complications such as bleeding, infection and growth of residual cancer cells. Chemotherapy and radiotherapy are highly toxic in that they cause death of not only cancerous cells, but normal cells as well. The current combination chemotherapy used to treat ovarian cancer usually includes the taxane, paclitaxel, plus a platinum containing compound such as carboplatinin or cisplatinin (McGuire, 1998; Young and Plosker, 2001 ). Sequentially used in recurrent disease, these agents may improve survival and/or quality of life. However, despite treatments such as these, the overall 5-year survival rate for ovarian cancer patients is slightly higher than 40% (Jemal et al., 2005) . There has been a significant amount of research in recent years about the efficacy of using new chemotherapeutic drugs/reagents to treat ovarian cancer. However, the true aim of salvage chemotherapy in relapsed ovarian cancer still remains palliative care, because complete responses are very rarely reported and long lasting responses are very seldom observed. Taking this into account, it is clear that an effective late stage therapy for ovarian cancer is desirable. There are several clinical trials sponsored by National Cancer Institute (www.clinicaltrials.nci.nih.gov), one of which is utilizes retinoids in cancer therapy.
Effects of retinoids on cancer cells
Various retinoids have been shown to be effective as chemotherapeutic and chemopreventive agents for a number of human cancers (Hong and Itri, 1994; De Luca et al., 1995; Zhang et al., 2000) . Presently, ATRA is used for the management of acute promyelocytic leukemia (APL). Different laboratories have shown that retinoids inhibit both tumor promotion and conversion of benign lesions to malignant lesions in skin, breast, bladder, lung, cervical, pancreatic and oral cancers in experimental animals (Hong et al., 1986; De Luca et al., 1995; Zhang et al., 2000) . Retinoids play important diverse roles in regulation of cellular growth, development and differentiation. Interest in retinoids as a potential chemotherapeutic agent arises from the fact that the growth of a number of tumor cells is suppressed by treatment with ATRA. More specifically, the ability of retinoids to inhibit the growth and cell cycle progression of ovarian carcinoma cell lines has been studied by a number of laboratories including our own (Grunt et al., 1991; Harant et al., 1993; Saunders et al., 1995; Chao et al., 1997; Wu et al., 1997a Wu et al., , b, 1998a Sabichi et al., 1998; Pergolizzi et al., 1999; Um et al., 2001; Zhang et al., 2001 ).
Rb2/p130 as a mediator of ATRA-induced growth suppression of ovarian carcinoma
Our laboratory prepared single cell clones from two ovarian carcinoma cell lines, CA-OV3 and SK-OV3, and analysed the effect of ATRA treatment on cell division, DNA synthesis, and cell cycle stage distribution of these single cell clones (Wu et al., 1997a) and cell cycle gene expression (Zhang et al., 2000 (Zhang et al., , 2001 . Our results show that despite the well-known heterogeneous nature of these cell lines, all single cell clones of SK-OV3 cells were resistant to the growth inhibitory effects of ATRA. In contrast, all single cell clones of CA-OV3 cells were growth inhibited by ATRA. However, the extent of growth inhibition did vary somewhat from clone to clone. Additional studies employing flow cytometry showed that ATRA blocked CA-OV3 cell cycle progression in the G1 stage. Finally, ATRA was able to inhibit G1 progression in growth-arrested CA-OV3 cells following stimulation with fetal bovine serum, insulin, IGF-1 or estrogen. As each of these growth factors is known to act via distinct signal transduction pathways, our results suggest that ATRA blocks G1 progression by targeting a downstream process or event, which occurs at a point after the insulin/IGF-1, estrogen and serum signal transduction pathways converge.
Additional experiments have demonstrated an increase in the protein levels of the Rb family member protein, Rb2/p130 (Zhang et al., 2000 (Zhang et al., , 2001 . This increase was found to be the result of a clear increase in the stability of Rb2/p130 protein in ATRA-treated cells compared to ethanol-treated cells. ATRA treatment increases the half-life of the Rb2/p130 protein from 12 h to greater than 40 h (Zhang et al., 2001) . This experiment suggests that the increases in Rb2/p130 following ATRA-treatment result from post-transcriptional/posttranslational modifications.
Ubiquitination of Rb2/p130 in ATRA-treated cells
To ascertain the mechanism responsible for the reduced degradation of the Rb2/p130 protein in ATRA treated CAOV3 cells we analysed the ubiquitin proteasome system. A number of other laboratories have shown that ATRA affects the proteasome dependent degradation of a number of cell cycle proteins. Borriello et al. (2000) have shown that ATRA treatment of neuroblastoma cells causes an increase in the CDKI protein p27/Kip1, through a mechanism involving decreased proteasomal degradation. On the other hand, CDK4 has been shown by another group to be degraded more rapidly following treatment with ATRA in human bronchial epithelial cells when compared to controls (Sueoka et al., 1999) . Whether the effect is an increase or decrease in proteasomal degradation, it is clear from our studies as well as the work of others that ATRA can have an effect on the ubiquitin-proteasome system. Rb2/p130 protein level increases in CAOV3 cells following treatment of these cells with the proteasome inhibitor clasto-lactacystin-b-lactone (CLBL) (Vuocolo et al., 2003) . This inhibitor is the active metabolite of the previously described proteasome inhibitor lactacystin, and has been shown to be a specific inhibitor of the proteasome (Craiu et al., 1997; Fukuchi et al., 1999) . This result indicates that the proteasome is responsible for degradation of Rb2/p130 in CAOV3 cells, and that this system could possibly be modified by ATRA treatment. We next determined the extent of ubiquitination of the Rb2/p130 protein following ATRA treatment of CAOV3 cells. After treating CAOV3 cells with CLBL alone, or ATRA þ CLBL, samples were immunoprecipitated with Rb2/p130 antibody. The subsequent Western blot was then probed with an antibody to ubiquitin to assess the amount of ubiquitinated Rb2/ p130. Interestingly, there was a clear decrease in the amount of ubiquitinated Rb2/p130 detected in CAOV3 cells following ATRA treatment (Vuocolo et al., 2003) .
Increased Rb2/p130 stability caused by ATRA is mediated by PP2A
Although the phosphorylation of the Rb2/p130 protein has been extensively studied, the de-phosphorylation of this protein is not yet well characterized. Rb2/p130 has three apparent phosphorylation states (Baldi et al., 1995; Mayol et al., 1996; Stiegler and Giordano, 1999; Canhoto et al., 2000) . These species can be distinguished by their migration on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and are presumably produced by various phosphorylations of the many CDK sites on Rb2/p130. The two faster migrating forms are stable and characteristic of the G0 state of the cell cycle while the third, slowest migrating form is the most hyperphosphorylated and targets the protein for degradation (Bhattacharya et al., 2003) . Degradation of Rb2/p130 consequently leads to progression through the cell cycle. It is most likely that this third, hyperphosphorylated species results from phosphorylation of CDK4-specific sites, converting the protein from form two to form three and leading to its subsequent degradation. Although the phosphorylation of the Rb2/p130 protein has been extensively studied, the dephosphorylation of this protein was not well characterized before our studies in ATRA growth arrested ovarian carcinoma cells. It is known, however, that certain serine/threonine phosphatases act to de-phosphorylate the closely related protein Rb (Mittnacht, 1998; Yan and Mumby, 1999) , and therefore activate its growth suppressive functions. Furthermore, a direct interaction between the serine threonine phosphatase PP1 and Rb has recently been detailed (Dunaief et al., 2002) .
Our laboratory was able to detect a specific interaction between protein phosphatase 2A and Rb2/p130 in CAOV3 ovarian carcinoma cells following ATRA treatment (Vuocolo et al., 2003) ; Purev et al., 2006a) . This interaction has been found to be specific to the C terminus of the Rb2/p130 protein, and it is also an active association, as PP2A serine/threonine phosphatase activity can be immunoprecipitated with Rb2/p130. We also found that PP2A mRNA and protein levels increased following ATRA treatment of CAOV3 ovarian carcinoma cells. This is supported by the findings of Chen et al. (2002) who has recently shown that expression of PP2ACa mRNA is regulated by retinoid receptors during development. These findings explain the dephosphorylation of Rb2/p130 protein following ATRA treatment that has been observed previously in our laboratory (Zhang et al., 2001) . It also explains the decrease in ubiquitination of the Rb2/p130 protein following ATRA treatment, as the ubiquitination of many cell cycle proteins is reliant on phosphorylation (Iqbal and Grundke-Iqbal, 1991; Spinella et al., 1999; Tsvetkov et al., 1999) (for a review see Wilkinson, 2000) .
Inhibition of PP2A phosphatase activity by chemical inhibitors such as fostriecin and okadaic acid results in hyperphosphorylation of Rb2/p130 Vuocolo et al., 2003) . This result supports the notion that PP2A dephosphorylates Rb2/p130 in CAOV3 cells. We have also shown through the use of siRNA, that PP2A upregulation is an important requirement for the growth inhibition of CAOV3 cells mediated by ATRA. Failure to increase PP2A levels following ATRA treatment by siRNA led to a significant reduction in the extent of growth suppression following ATRA treatment.
Our data suggest that ATRA treatment leads to the partial hypophosphorylation of Rb2/p130, which is caused by increased PP2A level/activity. We believe that the increased stability of Rb2/p130 in response to ATRA treatment occurs as a result of its hypophosphorylation. Our data also suggest that it is this increased Rb2/p130 protein stability that is, at least in part, responsible for the growth inhibition seen in CAOV3 cells following ATRA treatment. Studies reported by Yan and Mumby (1999) showed that there are distinct roles for both PP1 and PP2A in the dephosphorylation of the retinoblastoma protein under normal conditions. Our results demonstrate that PP2A is a phosphatase exhibiting increased protein expression (catalytic subunit alpha) and activity in CAOV3 cells treated with ATRA.
Nuclear transport of Rb2/p130
Proteins with molecular weight greater than B10-20 kDa, including Rb2/p130, are selectively and actively transported through the nuclear pore complex (NPC) whereas small macromolecules can passively diffuse through NPC (Stochaj et al., 1993; Koepp et al., 1996; Fahrenkrog et al., 2004) . The distribution of Rb2/p130 in the cell varies depending on the cell cycle state. During the G0/G1 phase of the cell cycle, the amount of Rb2/p130 protein is elevated in the nuclear fraction when compared to the cytoplasmic fraction. At G1/S, cytoplasmic Rb2/p130 protein is slightly increased, and in the S-phase, both nuclear and cytoplasmic Rb2/p130 is significantly reduced (Chestukhin et al., 2002) . Therefore, in addition to escaping proteasomal degradation, Rb2/p130 must be transported into the nucleus for it to affect cell cycle arrest. The import signal in nuclear proteins is the NLS, which consists of one or more clusters of predominantly basic amino acids-lysines, prolines and arginines.
There are several NLS sites in the Rb2/p130 protein. Two of these are localized within the C-terminal region of the protein while one is found in the pocket region (Zacksenhaus et al., 1999; Cinti et al., 2000; Chestukhin et al., 2002) . NLS sequences located in the C-terminus of Rb2/p130 are also the sites of interaction with PP2Ac (Vuocolo et al., 2003; Purev et al., 2006a) . We and others found by site-specific mutagenesis that the NLS in the C-terminal end possesses the SPSKRLRE (NLS1) and TPTKKRGI (NLS2) and that NLS mutants of Rb2/p130 are impaired in nuclear transport (Chestukhin et al., 2002; Cinti et al., 2000; Purev et al., 2006a) . More specifically, mutation of either the NLS1 or NLS2 sites individually resulted in the nuclear localization of Rb2/ p130-COOH peptide; however, combined mutation of both NLS leads to the cytoplasmic retention of Rb2/ p130. Interestingly, there are serine (S1080) and threonine (T1097) residues located next to these NLS sequences. Despite multiple serine and threonine residues in the COOH region, only S1080 and T1097 have been found to be phosphorylated in vivo (Hansen et al., 2001) . We found that PP2Ac binds to the NLS1 and NLS2 sites and is capable of de-phosphorylating these specific serine and threonine residues (Purev et al., 2006a) .
Nuclear transport proteins
Among the many proteins known to be involved in classical transport of NLS containing proteins, importin a karyopherin a and importin b (karyopherin b) have been shown to play important roles. Importin a is a B60 kDa protein that specifically recognizes NLS sequences. There are several isoforms of human importin a, designated a-1, a-2, a-3, a-4, a-5 and a-6, which share high homology and appear to have some substrate specificity not only by virtue of differential tissue localization but also different substrate affinity. It consists of hydrophilic amino-terminal and carboxylterminal regions and a large central domain that consists of tandemly repeated modules known as 'armadillo' or arm-repeats. The NLS-binding domain of importin a is located in the 'armadillo' motif and is surrounded by acidic amino acids. Negatively charged amino acids arrayed along the outer edge of the NLS-binding site on importin a form electrostatic interactions with positively charged amino acids on the NLS peptide in addition to hydrophobic and van der Waals interactions (Corbett and Silver, 1997; Harreman et al., 2004) . Phosphorylation of serine/threonine in and/or adjacent to the NLS adds a negatively charged phosphate group which disrupts electrostatic interactions between NLS and importin a and decreases interaction of the two proteins (Kehlenbach and Gerace, 2000; Harreman et al., 2004; Sekimoto et al., 2004) .
Importin b is a B92 kDa protein which interacts with importin a through its huntingtin-elongation-A-subuni-TOR (HEAT) motif, important for mediating proteinprotein interaction. There are three known human isoforms: b1, b2 and b3. Importin b interacts with importin a and other proteins, which constitute the NPC. A model has been developed in which importin a recognizes NLS and importin b targets the complex to the nucleus (Corbett and Silver, 1997) . However, it is well known that affinity between importin a and NLS dramatically increases in the presence of importin b by exposing the 'amadillo' region to NLS protein and preventing importin a dimerization (Conti et al., 1998; Catimel et al., 2001) .
In numerous cases, transport of NLS cargo is regulated by phosphorylation (Kaffman and O'Shea, 1999; Jans et al., 2000; Harreman et al., 2004) . There are several ways in which phosphorylation could regulate protein import into the nucleus. As described previously, phosphorylation could directly modulate the affinity of NLS protein with importin a, by disrupting the electrostatic interaction between proteins (Figure 4 ). Phosphorylation could also cause the binding and release of an NLS masking protein (Shirakawa and Mitzel, 1989) .
Role of PP2Ac interaction in mediating nuclear transport of Rb2/p130
As mentioned previously, NLS mutants of Rb2/p130 are impaired in nuclear transport and the NLS1 and NLS2 sequences located in the C-terminus of Rb2/p130 contain serine and threonine residues which are known to be phosphorylated in vivo by CyclinD/Cdk4 (Hansen et al., 2001; Vuocolo et al., 2003) . We have recently demonstrated that PP2A binds directly to these NLS sites and purified PP2A catalytic subunit can dephosphorylate S1080 and T1097 (Purev et al., 2006a, b) . Moreover, mutation of either C-terminus NLS in Rb2/ p130 either partially or completely inhibits interaction with PP2Ac (Purev et al. 2006b ). Also, we have shown that ATRA treatment of ovarian carcinoma cells leads to increased accumulation of Rb2/p130 protein in the nucleus and disruption of the interaction of Rb2/p130 with PP2A by mutation of the C-terminal NLS leads to a significant reduction in the trafficking of Rb2/p130 to the nucleus (Purev et al., 2006a, b) .
In studies designed to elucidate whether the interaction of PP2A and Rb2/p130 C-terminal NLS mediates nuclear trafficking, we observed that both importin a and importin b found in whole cell extracts of CA-OV3 ovarian carcinoma cells, interact with Rb2/p130-COOH and the extent of interaction increased following ATRA treatment. Mutation of either NLS1 or NLS2 of Rb2/ p130-COOH significantly reduced binding of importin a to Rb2/p130 while mutation of both NLS1 and NLS2 completely eliminated binding of importin a to Rb2/ p130 (Purev et al., 2006b) . PP2A and importin a appear to bind to the same region of Rb2/p130 but the importin a binds to the NLS sites of Rb2/p130 to a greater extent than PP2Ac. It is known that interaction of importin a with NLS is abrogated when the NLS is phosphorylated (Conti et al., 1998; Harreman et al., 2004) . We showed that the mimicking of phosphorylation of the S1080 and T1097 residues, located adjacent to the NLS1 (SPSKRLRE) and NLS2 (TPTKKRGI), by substitution of the serine and threonine with glutamic acid (EPSKRLRE and EPTKKRGI) abrogated the ability of Rb2/p130 to translocate to the nucleus (Purev et al., 2006b) . These results suggest that S1080 and T1097 must be dephosphorylated in order for Rb2/p130 to be transported to the nucleus. As PP2Ac interacts with the NLS1 and NLS2 on Rb2/p130 C-terminus it is likely that in ATRA treated CA-OV3 cells, PP2Ac dephosphorylates S1080 and T1097, leading to binding of Rb2/p130 to importin a followed by interaction with importin b resulting in subsequent translocation of Rb2/ p130 to the nucleus where it acts to suppress the growth of CA-OV3 cells ( Figure 5 ).
Interaction of Rb2/p130 and PP2A mediated by ATRA leads to suppression of growth of ovarian cancer cells
As discussed previously, we have reported that ATRA treatment increases Rb2/p130 protein level by reducing its phosphorylation and protecting it from ubiquitinproteasomal degradation (Vuocolo et al., 2003; Purev et al., 2006a) . We and others (Cicchillitti et al., 2003; Vuocolo et al., 2003; Purev et al., 2006a) showed interaction between Rb2/p130 C-terminus with protein phosphatase 2A, which in turn enhances dephosphorylation of Rb2/p130, interaction of the Rb2/p130 with importin a and importin b and transport of the Rb2/ p130 to the nucleus. In additional studies designed to demonstrate the physiological significance of these interactions, we found that CA-OV3 cells that overexpress wt Rb2/p130-COOH, a truncated Rb2/p130 protein containing only the COOH terminus, proliferated more rapidly and were resistant to growth suppression following ATRA treatment (Table 1) (Purev et al., 2006a) . Moreover, when NLS1 and NLS2 mutated Rb2/p130-COOH was overexpressed we did not see any changes in the growth and sensitivity of CAOV3 cells to ATRA treatment (Table 1) . These results suggested that Rb2/p130-COOH could act as a dominant negative protein, which could sequester PP2Ac, thereby competing with the endogenous Rb2/ p130 for binding to PP2A. The endogenous Rb2/p130, which does not associate with PP2A is hyperphosphorylated, undergoes ubiquitin-proteasomal degradation, and thus less Rb2/p130 accumulates in the nucleus. In contrast, overexpressed NLS-mutated Rb2/p130-COOH does not to bind PP2Ac. As a result, PP2A interacts with the endogenous Rb2/p130, dephosphorylates the NLS, leading to Rb2/p130 accumulation in the nucleus and growth suppression. This demonstrates the importance of Rb2/p130-PP2A interaction in mediating suppression of growth by ATRA. In addition, ATRA increases the level of PP2Ac while reducing the level of phosphorylated PP2Ac. As phosphorylation of PP2Ac reduces its enzymatic activity, ATRA treatment significantly also increases PP2Ac activity, coinciding with the reduced phophorylation of PP2Ac (Purev et al., 2006a) . 
Mechanisms of growth regulation by Rb2/p130
The growth regulatory activities associated with Rb2/ p130 are mediated by its phosphorylation state, as this is clearly cell cycle regulated (Baldi et al., 1995; Canhoto et al., 2000; Hansen et al., 2001) , and Rb2/p130 has been shown to be a substrate for cyclin/cyclin-dependent kinase (CDK) complexes. The molecular interactions concerning growth inhibition by Rb2/p130 and the Rb family in general can be complex. The increased stability of Rb2/p130 following ATRA treatment allows the protein to remain active for a longer duration, generally slowing cell cycle progression, and eventually cell growth. It can do this via an array of mechanisms including:
CDK2 inhibition
The mammalian cell cycle requires the coordinated expression of various cyclins and cyclin dependent kinases in order to proceed through G1, as well as S-phase and G2/M. Aside from inhibition of E2F, Rb2/ p130 as well as close family member p107 are thought to suppress growth through their associations with two important cell cycle complexes, cyclin A-CDK2, and cyclin E-CDK2. Inhibition of cyclin E activity, or cyclin E associated kinase activity halts the cell cycle in G1, as they are unable to pass beyond the restriction point governed primarily by the Rb family. Rb2/p130 as well as Rb must be phosphorylated and therefore inactivated by cyclinA/E-CDK2 (and CDK4) in order for cells to progress through G1. Rb2/p130 is able to directly inhibit the kinase activity of cyclin-dependent kinase 2 through both the spacer region (De Luca et al., 1997) , and the N terminus (Woo et al., 1997) . This is in contrast to the close relative p107, which is also able to inhibit CDK2 activity, though its suppressive functions are confined to its C terminus. It is hypothesized that the inhibition of CDK2 activity by Rb family proteins is the result of a direct interaction between specific sequences in the domains of these proteins and the kinase.
Repression of E2F
Rb2/p130 is known to bind to the E2F family of transcription factors (Claudio et al., 1996; Mayol et al., 1996; Grana et al., 1998; Mayol and Grana, 1998) . This actively sequesters E2F (E2F's 4 and 5 for Rb2/p130), a powerful transcription factor which controls the expression of genes required for progression through the cell cycle including cdc25a (Iavarone and Massague, 1999) , cyclin D (Watanabe et al., 1998) , and cyclin E (Schulze et al., 1995; Botz et al., 1996; Spitkovsky et al., 1997) . Promoters of genes that control DNA replication, such as dihydrofolate reductase (Wade et al., 1995; Fry et al., 1997) , and thymidine kinase (Ogris et al., 1993; Dou et al., 1994; Hengstschlager et al., 1996) are also under the auspices of the E2F family.
Nucleocytoplasmic shuttling of Rb2/p130 and E2F Cellular compartmentalization of E2F transcription factors is cell cycle dependent. Several laboratories have demonstrated that as cells progress from G1 to S phase, E2F4 is translocated from the nucleus to the cytoplasm (Lindeman et al., 1997; Muller et al., 1997; Verona et al., 1997) . This inherently suggests that sequestration or shuttling of E2F4 may provide an additional level of transcriptional control. E2F 1, 2 and 3 have nuclear localization signals, while E2F4 and 5 do not (Lindeman et al., 1997; Muller et al., 1997) . There must then be other accessory proteins, which are able to bind to E2F4 and 5 and promote their entry into the nucleus. Evidence suggests that Rb2/p130 may be one such protein. Using an interspecies heterokaryon assay, Chestukhin et al. (2002) were able to observe Rb2/ p130 shuttling between the cytoplasm and nucleus. They were also able to identify several independent nuclear localization signals in the C terminus, the unique 'loop' region, and the pocket.
In addition, the N terminal region of Rb2/p130 conferred cytoplasmic localization. Taken together, these results indicate not only that Rb2/p130 can shuttle between the nucleus and cytoplasm, contributing to its own regulation, but that it may be able to confer an additional level of regulation on E2F4 and 5, serving as a shuttle and moving the proteins in and out of the nucleus.
Future directions
The mechanisms by which ATRA causes growth inhibition of ovarian carcinoma cells are complex. Our lab has identified several distinct mechanisms to date, which bring to light the multifunctional activities of ATRA. We have identified changes in proteins such as Rb2/p130 and PP2A. These proteins are upregulated in response to ATRA treatment and cause a response via their normal activities, which are to slow cell growth through several mechanisms summarized earlier. Our studies are the first to identify definitively the binding of PP2A to the Rb2/p130 protein. This is significant in that the dephosphorylation of the Rb family is not yet well understood. Moreover, follow-up studies by our laboratory are the first to show that the interaction of PP2A with Rb2/p130 C-terminus plays an important role in translocating Rb2/p130 to the nucleus by mediating interaction of the Rb2/p130 with the nuclear transport proteins importin a and importin b.
Understanding the molecular mechanism of ATRAmediated growth arrest will allow us to design more effective therapy for ovarian cancer. For example, based on our findings, assays for Rb2/p130 protein level, Rb2/ p130 phosphorylation status, mutations in Rb2/p130 NLS sequences, PP2A activity and presence of Rb2/ p130 in the nucleus could provide invaluable prognostic tools to evaluate the efficacy of ATRA treatment for late stage ovarian cancer. Likewise, modulation of these proteins through gene therapy could be used to increase sensitivity of drug resistant ovarian tumor cells to retinoid treatment. Finally, high throughput screening could be used to identify compounds, which modulate these proteins similarly to ATRA leading to development of a more effective therapy against drug resistant ovarian carcinoma tumor cells.
